Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lower blood lipid levels beneficial for kidney patients

29.11.2010
Good news for kidney patients: Blood lipid lowering drug treatment reduces the risk of life-threatening cardiovascular diseases in these patients as well. This is the result of a clinical trial, involving almost 10,000 patients.

A quarter of all heart attacks, strokes and operations to open blocked arteries could be avoided in patients with chronic kidney diseases – if the patients take a long term treatment of the blood lipid lowering drugs ezetimibe and simvastatin.

"In this way, about 250,000 people worldwide could be spared from this cardiovascular disease," says principal investigator Professor Colin Baigent of the University of Oxford.

This is the conclusion of the so-called Sharp study, the results of which were presented for the first time at the Nephrology Convention held in the United States on 20 November. This is the largest study of kidney patients ever conducted: It included altogether 9,480 patients from more than 380 hospitals in 18 countries over a time span of ten years. About one third of the patients had already progressed to the stage of dialysis.

Würzburg recruited 1,800 patients

The Department of Medicine I of the University of Würzburg served as a coordinating center for Germany and Austria. Professor Christoph Wanner was the regional coordinator for Central Europe; Associate Professor Vera Krane acted as a study coordinator. "We started the planning in collaboration with Oxford in spring 2001," says Professor Wanner. He and his team recruited altogether 1,800 patients for the study.

The risk of heart attacks and strokes is very high in patients with chronic kidney disease. "Previously, in the prevailing scientific opinion, the higher risk was not thought to be connected to the blood lipid levels so that a reduction of the blood lipid levels would seem to be of no benefit to the patients," says Professor Wanner. This opinion can now be rejected. The fact that blood lipid lowering drugs reduce the risk of cardiovascular diseases in healthy people has long been known.

Side effects of the treatment

"There was no evidence in the study of any adverse side effects of the treatment," says co-principal investigator Martin Landray from Oxford. Earlier concerns that ezetimibe might cause cancer were not confirmed either: "The study clearly shows that the treatment is safe."

Information on chronic kidney disease

Chronic kidney disease is a slowly progressing loss in kidney function over a period of several years. The people most at risk are diabetics, smokers, overweight people and patients with high blood pressure. At the end stage, the kidney function drops to only 15 percent or less. When this stage is reached, renal treatment in form of dialysis or a transplant is required. According to the SHARP study, a reduction of the blood lipid levels is beneficial in any case – no matter how far the disease has already progressed.

Contact person

Prof. Dr. Christoph Wanner, Department of Medicine I, Nephrology Department, University of Würzburg, T +49 (0)931 201-36330, christoph.wanner@uni-wuerzburg.de

Robert Emmerich | idw
Further information:
http://www.sharpinfo.org

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Designer cells: artificial enzyme can activate a gene switch

22.05.2018 | Life Sciences

PR of MCC: Carbon removal from atmosphere unavoidable for 1.5 degree target

22.05.2018 | Earth Sciences

Achema 2018: New camera system monitors distillation and helps save energy

22.05.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>